Clopidogrel Prices, Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data Report 2026 Edition
Clopidogrel Price Trend, Index and Forecast
Track the latest insights on clopidogrel price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Clopidogrel Prices Outlook Q1 2026
- China: USD 34890/MT
- Chile: USD 52196/MT
- South Korea: USD 41619/MT
- India: USD 36947/MT
- Indonesia: USD 66611/MT
Clopidogrel Price Chart
Get real-time access to monthly/quarterly/yearly prices Request Sample
During the first quarter of 2026, the clopidogrel prices in China reached 34890 USD/MT in March. Prices moved lower through the quarter as domestic producers maintained steady operating rates and inventories remained sufficient across the pharmaceutical supply chain. Buyers adopted a cautious procurement stance due to softer downstream demand from formulation units and limited urgency for restocking.
During the first quarter of 2026, the clopidogrel prices in Chile reached 52196 USD/MT in March. The market weakened as import availability improved and distributors showed limited interest in fresh procurement. Pharmaceutical buyers relied on previously secured inventories, which reduced spot market activity. Demand from local formulation and healthcare channels remained steady but lacked enough strength to support higher offers.
During the first quarter of 2026, the clopidogrel prices in South Korea reached 41619 USD/MT in March. Prices declined as domestic buyers maintained conservative purchasing plans and avoided building excess inventories. Supply from regional producers remained adequate, while import channels from China and India stayed active. Pharmaceutical manufacturers focused on need based procurement due to stable end use demand and pressure to control input costs.
During the first quarter of 2026, the clopidogrel prices in India reached 36947 USD/MT in March. The market recorded a downward movement as domestic manufacturing activity remained stable and product availability improved. Formulation producers purchased cautiously, supported by adequate inventories and softer expectations for near term demand. Export interest was present but not strong enough to offset pressure from competitive supplier offers.
During the first quarter of 2026, the clopidogrel prices in Indonesia reached 66611 USD/MT in March. Prices moved lower as importers faced softer replacement costs and reduced buying urgency from downstream pharmaceutical buyers. Local distributors maintained cautious inventory strategies due to stable but restrained demand from formulation channels. Availability from Asian suppliers remained comfortable, which increased competition among sellers and supported price concessions.
Clopidogrel Prices Outlook Q3 2025
- China: USD 38790/MT
- Chile: USD 55350/MT
- South Korea: USD 44280/MT
- India: USD 43100/MT
- Indonesia: USD 77500/MT
During the third quarter of 2025, the clopidogrel prices in China reached 38790 USD/MT in September. Prices moved downward as export demand from regulated pharmaceutical markets softened. Reduced procurement from overseas formulation units and sufficient domestic availability influenced sourcing behavior. Buyers focused on inventory management and aligned purchases with confirmed export and domestic formulation requirements.
During the third quarter of 2025, the clopidogrel prices in Chile reached 55350 USD/MT in September. Prices declined amid weaker public healthcare procurement and slower distributor purchasing activity. Reduced tender participation influenced demand visibility. Buyers limited sourcing volumes and structured procurement around confirmed supply commitments.
During the third quarter of 2025, the clopidogrel prices in South Korea reached 44280 USD/MT in September. Prices increased as demand from regulated pharmaceutical formulation and export-oriented manufacturing strengthened. Improved order visibility supported procurement activity. Buyers coordinated sourcing with production schedules, regulatory documentation, and distributor requirements.
During the third quarter of 2025, the clopidogrel prices in India reached 43100 USD/MT in September. Prices moved downward due to moderated export demand and cautious buying from formulation units. Adequate production capacity and inventory availability influenced procurement strategies. Buyers emphasized short-cycle sourcing aligned with confirmed manufacturing needs.
During the third quarter of 2025, the clopidogrel prices in Indonesia reached 77500 USD/MT in September. Prices declined as demand from domestic pharmaceutical manufacturers and healthcare distributors softened. Slower procurement from public healthcare channels influenced sourcing decisions. Buyers focused on inventory optimization and near-term operational requirements.
Clopidogrel Prices Outlook Q2 2025
- China: USD 39500/MT
- Chile: USD 56828/MT
- South Korea: USD 42950/MT
- India: USD 44990/MT
- Indonesia: USD 79162/MT
During the second quarter of 2025, the clopidogrel prices in China reached 39500 USD/MT in June. Demand from export-oriented pharmaceutical manufacturers and domestic formulation units shaped procurement activity. Buyers coordinated sourcing with production planning, regulatory timelines, and inventory management strategies.
During the second quarter of 2025, the clopidogrel prices in Chile reached 56828 USD/MT in June. Procurement was influenced by public healthcare supply programs and distributor-led sourcing. Buyers aligned purchases with tender schedules, inventory planning, and confirmed supply requirements.
During the second quarter of 2025, the clopidogrel prices in South Korea reached 42950 USD/MT in June. Demand from regulated pharmaceutical manufacturing and export-focused formulation guided sourcing decisions. Buyers coordinated procurement with compliance documentation and distributor commitments.
During the second quarter of 2025, the clopidogrel prices in India reached 44990 USD/MT in June. Procurement activity reflected demand from domestic formulation units and export markets. Buyers structured sourcing around production schedules, regulatory requirements, and inventory planning.
During the second quarter of 2025, the clopidogrel prices in Indonesia reached 79162 USD/MT in June. Demand from pharmaceutical manufacturers and healthcare distributors influenced procurement volumes. Buyers aligned sourcing with operational requirements and distributor coordination.
Regional Coverage
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing clopidogrel prices.
Europe Clopidogrel Price Trend
Q1 2026:
The clopidogrel price index in Europe moved under pressure as buyers remained cautious and focused on inventory control. Pharmaceutical manufacturers maintained regular procurement, but demand was largely tied to confirmed production schedules rather than stock building. Import availability from Asian suppliers improved, giving European buyers greater negotiating strength. Softer upstream intermediate costs also reduced supplier confidence and encouraged flexible offers. Distributors avoided carrying excess volumes due to uncertain short term consumption patterns and pressure on working capital.
Q3 2025:
As per the clopidogrel price index, demand was shaped by regulated pharmaceutical manufacturing and steady healthcare consumption across hospital and retail channels. Buyers coordinated procurement with strict regulatory compliance, batch certification, and documentation requirements. Sourcing decisions were closely aligned with formulation schedules and distributor commitments. Import dependency influenced lead times, while procurement strategies emphasized ensuring uninterrupted supply for cardiovascular treatment programs across key European markets.
Q2 2025:
During the second quarter, clopidogrel procurement in Europe reflected routine sourcing to support ongoing pharmaceutical manufacturing and healthcare distribution. Buyers coordinated purchases around regulatory documentation timelines, quality audits, and distributor inventory planning. Demand was supported by stable prescription volumes across major European markets. Procurement strategies centered on operational continuity, supplier reliability, and adherence to compliance standards rather than short-term market adjustments.
Detailed price information for clopidogrel can also be provided for an extensive list of European countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North America Clopidogrel Price Trend
Q1 2026:
The clopidogrel price index in North America experienced varied trends as import supply stayed sufficient and buyers resisted higher offers. Pharmaceutical companies continued to purchase according to immediate production needs, limiting broad market momentum. Distributors managed inventories carefully after earlier procurement cycles, which reduced spot buying activity. Asian suppliers remained competitive, adding pressure on regional sellers and weakening bargaining power. Input cost support was limited, which allowed sellers to adjust quotations to secure orders. Demand from cardiovascular drug formulation remained steady, but the absence of strong restocking kept prices under pressure.
Q3 2025:
As per the clopidogrel price index, in North America, clopidogrel procurement reflected demand from pharmaceutical formulation units supplying hospital networks and retail pharmacies. Buyers aligned sourcing with production planning, inventory management, and regulatory approval timelines. Distributor-led procurement and healthcare system requirements influenced purchase volumes. Established supply chains and import availability supported continuity, with sourcing decisions focused on meeting confirmed prescription demand and maintaining supply reliability.
Q2 2025:
Clopidogrel demand in North America reflected planned procurement aligned with pharmaceutical production schedules and healthcare distribution planning. Buyers structured sourcing around inventory replenishment cycles, regulatory compliance, and distributor coordination. Hospital formulary requirements and retail pharmacy stocking policies influenced procurement volumes. Sourcing strategies focused on maintaining dependable supply coverage across public and private healthcare channels.
Specific clopidogrel historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Middle East and Africa Clopidogrel Price Trend
Q1 2026:
According to the clopidogrel price chart, supply chain interruptions, seasonal variations in demand, and geopolitical influences were the main causes of the price fluctuations in the Middle East and Africa.
Q3 2025:
As per clopidogrel price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
Q2 2025:
The report explores the clopidogrel pricing trends and clopidogrel price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
Region-wise data and information on specific countries within these regions can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Clopidogrel Price Trend
Q1 2026:
In the Asia Pacific, clopidogrel prices declined as production centers maintained stable operating rates and regional supply stayed comfortable. China and India continued to influence pricing through competitive offers, while buyers in South Korea, Indonesia, and other markets avoided aggressive restocking. Formulation demand remained regular, supported by ongoing cardiovascular medicine requirements, but it did not generate enough pressure to lift prices. Downstream buyers focused on cost reduction and waited for more favorable offers before committing to larger volumes.
Q3 2025:
As per the clopidogrel price index, Asia Pacific experienced mixed price movement, shaped by declines in China, India, and Indonesia and an increase in South Korea. Softer export demand and cautious procurement reduced sourcing activity in China and India, while stronger demand from regulated formulation and export-oriented manufacturing supported South Korean consumption. Buyers adjusted sourcing strategies based on country-specific demand visibility. Domestic production capacity and regional trade flows supported material availability across key pharmaceutical manufacturing hubs.
Q2 2025:
In Asia Pacific, clopidogrel demand during the second quarter was driven by pharmaceutical formulation activity across China, South Korea, India, and Indonesia. Buyers coordinated sourcing with production planning, regulatory timelines, and downstream order visibility. Domestic production capacity and regional supply networks supported continuity, while procurement strategies emphasized operational alignment and batch traceability.
This clopidogrel price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin America Clopidogrel Price Trend
Q1 2026:
In Latin America, clopidogrel prices moved lower as importers responded to softer offers from Asian suppliers. Regional demand from pharmaceutical distributors and formulation channels remained steady but cautious, with buyers limiting procurement to short term needs. Chile and other import dependent markets saw weaker landed cost expectations, which encouraged delayed purchasing and firmer negotiation from buyers. Suppliers faced pressure to adjust offers to keep cargo movement active.
Q3 2025:
As per the clopidogrel price index, Latin America experienced downward price movement, led by declines in Chile. Reduced public healthcare procurement and slower distributor purchasing softened regional consumption. Buyers limited sourcing volumes and aligned procurement with confirmed tender-based requirements. Import availability supported supply continuity, with sourcing decisions focused on near-term operational needs.
Q2 2025:
In Latin America, clopidogrel procurement reflected demand from public healthcare systems and pharmaceutical distributors. Buyers scheduled sourcing based on tender cycles, inventory planning, and distributor commitments. Import flows and logistics coordination supported material availability, with procurement focused on ensuring continuity of supply.
This comprehensive review can be extended to include specific countries within Latin America.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
Clopidogrel Pricing Report, Market Analysis, and News
IMARC's latest publication, “Clopidogrel Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” presents a detailed examination of the clopidogrel market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of clopidogrel at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed clopidogrel prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting clopidogrel pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.
Clopidogrel Industry Analysis
The global clopidogrel industry size reached USD 15.0 Billion in 2025. By 2034, IMARC Group expects the market to reach USD 33.7 Billion, at a projected CAGR of 9.10% during 2026-2034. Market growth is driven by sustained demand for antiplatelet therapies, expanding cardiovascular treatment programs, rising prevalence of lifestyle-related diseases, and continued pharmaceutical manufacturing activity across regulated and emerging healthcare markets.
Latest News and Developments:
- September 2025: An integrative pharmacogenomics study evaluated genetic and clinical predictors of clopidogrel response in South Indian coronary artery disease (CAD) patients. This research identifies high prevalence of CYP2C19 poor metabolizer variants and demonstrates how specific genetic polymorphisms significantly influence clopidogrel platelet inhibition and treatment outcomes.
- January 2024: Cosmos Health Inc. acquired a portfolio of 10 generic medications for approximately USD 3.5 million, enhancing its presence in the global generic drugs market. The drugs address various health issues, including diabetes and cardiac conditions, with manufacturing set to occur at its subsidiary, Cana Laboratories. Among the medications is clopidogrel, used for preventing blood clots.
Product Description
Clopidogrel is an antiplatelet drug that is commonly prescribed to patients with cardiovascular conditions, including heart attacks and strokes, to prevent blood clot formation. This pharmaceutical agent has the mechanism of reducing the ability of platelets to coagulate and thus the risk of clot formation in arteries is minimized. Clopidogrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist, ensures long-term platelet inhibition. As an oral medication, it is convenient for patients to take and has been proven effective when combined with aspirin to enhance the antithrombotic effect. It is particularly valued for its prolonged prevention of further thrombotic episodes, making it a crucial component in the treatment of cardiovascular diseases.
Report Coverage
| Key Attributes | Details |
|---|---|
| Product Name | Clopidogrel |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Clopidogrel Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of clopidogrel pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
- The study examines factors affecting clopidogrel price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The clopidogrel price charts ensure our clients remain at the forefront of the industry.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Request Customization
Inquire Before Buying
Speak to an Analyst
Request Brochure
Benefits of Customization
- Personalize this research
- Triangulate with your data
- Get data as per your format and definition
- Gain a deeper dive into a specific application, geography, customer, or competitor
- Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-201-971-6302
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: sales@imarcgroup.com
Client Testimonials
.webp)
.webp){kind=logo}
Why Choose Us
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
Robust Methodologies & Extensive Resources
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Subscription-Based Databases
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Primary Research-Driven Insights
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
Extensive Secondary Research
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.